Dr. Kakkis is Chief Executive Officer, President and a Director of Ultragenyx. He founded Ultragenyx in 2010 to create a company that is uniquely built around a deep and meaningful engagement with patients and their caregivers to fully understand their needs. This includes designing a novel development model that fundamentally changed the established paradigms in clinical protocols, endpoints and analyses, as well as challenging traditional beliefs around commercialization and access to therapies for patients with rare and ultra-rare genetic diseases.
Dr. Kakkis began at the Harbor-UCLA Medical center where he was developing an enzyme replacement therapy for the rare disorder MPS I. He joined Biomarin in 1998 where he guided the development and approval of three treatments for rare diseases (MPS I, MPS VI and PKU) and contributed to the development of approved or development stage products for four other rare diseases (CLN2, MPSIVA, PKU, achondroplasia). He has worked to advance the cause of rare disease treatment through advocacy on policy issues by founding and supporting the EveryLife Foundation for Rare Diseases, a non-profit foundation dedicated to the acceleration of biotech innovation for rare diseases through practical and scientifically sound improvements to development strategies, regulatory policy and law.
Dr. Kakkis received a Lifetime Achievement Award from the National MPS Society, the Roscoe O. Brady Award for Innovation and Accomplishment from the WORLDSymposium, and BIO’s Henri Termeer Visionary Leadership award for this transformative work in rare diseases.
Dr. Kakkis serves on the Board of Odylia Therapeutics and the EveryLife Foundation.
Dr. Kakkis graduated from Pomona College, magna cum laude, and received the Vaile prize for his biology research. He received combined M.D. and Ph.D. degrees from the UCLA Medical Scientist Program and received the Bogen Prize for his research upon graduation. He completed a pediatrics residency and a Medical Genetics Training Fellowship at Harbor-UCLA Medical Center, where he was an assistant professor of pediatrics and initiated the enzyme therapy program for MPS I. Dr. Kakkis was board certified in pediatrics and medical genetics.
What is Emil D. Kakkis' net worth?
The estimated net worth of Emil D. Kakkis is at least $105.06 million as of September 3rd, 2024. Dr. Kakkis owns 2,223,985 shares of Ultragenyx Pharmaceutical stock worth more than $105,061,051 as of November 23rd. This net worth estimate does not reflect any other assets that Dr. Kakkis may own. Additionally, Dr. Kakkis receives a salary of $1,460,000.00 as CEO at Ultragenyx Pharmaceutical. Learn More about Emil D. Kakkis' net worth.
How old is Emil D. Kakkis?
What is Emil D. Kakkis' salary?
How do I contact Emil D. Kakkis?
Has Emil D. Kakkis been buying or selling shares of Ultragenyx Pharmaceutical?
Who are Ultragenyx Pharmaceutical's active insiders?
Ultragenyx Pharmaceutical's insider roster includes William Aliski (Director), Camille Bedrosian (EVP), Eric Crombez (Chief Medical Officer and EVP), Mardi Dier (CFO), Matthew Fust (Director), Erik Harris (EVP), Howard Horn (CFO and EVP, Corporate Strategy), Dennis Huang (EVP), Theodore Huizenga (CAO), Emil Kakkis (CEO), Thomas Kassberg (EVP), Karah Parschauer (EVP), John Pinion (Insider), Corsee Sanders (Director), Shalini Sharp (CFO), and Clay Siegall (Director). Learn More on Ultragenyx Pharmaceutical's active insiders.
Are insiders buying or selling shares of Ultragenyx Pharmaceutical?
During the last twelve months, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 91,799 shares worth more than $4,701,943.08. The most recent insider tranaction occured on October, 10th when CFO Howard Horn sold 7,465 shares worth more than $393,853.40. Insiders at Ultragenyx Pharmaceutical own 5.8% of the company.
Learn More about insider trades at Ultragenyx Pharmaceutical. Information on this page was last updated on 10/10/2024.
